Joseph Suttner brings more than 20 years of experience in drug development across the biotechnology and pharmaceutical industries. He specializes in global clinical operations, rare disease programs, and late-stage development.

Before joining NFlection, Suttner served as Vice President of Clinical Operations at Attralus, where he led a cardiac-focused pan-amyloid program. He previously held the same role at PellePharm, a BridgeBio subsidiary, overseeing clinical programs for Gorlin syndrome and high-frequency basal cell carcinoma.

Earlier in his career, Suttner contributed to NDA and BLA submissions and strategic partnerships at Dermira and served as Vice President of Clinical Operations at Aimmune Therapeutics, where he established a global network of food allergy clinical centers in collaboration with patient advocacy groups. His experience also includes leadership roles at Amgen, Allergan, Ipsen, and Peplin Pharmaceuticals.